Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age

Autor:	Doering G, Louis Bont, Carbonell-Estrany X, Gouyon Jb, Marcello Lanari
Přispěvatelé:	Carbonell-Estrany, X., Bont, L., Doering, G., Gouyon, J-B., Lanari, M.
Rok vydání:	2008
Předmět:	Microbiology (medical) Palivizumab YOUNG-CHILDREN medicine.medical_specialty Pediatrics Cost effectiveness viruses macromolecular substances Respiratory Syncytial Virus Infections Antibodies Monoclonal Humanized Antiviral Agents Chemoprevention COST-EFFECTIVENESS Human metapneumovirus Lower respiratory tract infection medicine Humans PALIVIZUMAB PROPHYLAXIS BRONCHIOLITIS Intensive care medicine Respiratory Tract Infections PREMATURE-INFANTS REDUCES HOSPITALIZATION biology Respiratory tract infections HUMAN METAPNEUMOVIRUS business.industry RSV INFECTION Infant Newborn Gestational age Antibodies Monoclonal General Medicine Pneumovirus biology.organism_classification medicine.disease respiratory tract diseases LUNG-FUNCTION Infectious Diseases Bronchiolitis RISK-FACTORS Antibodies Monoclonal Humanized Antiviral Agents Palivizumab business Infant Premature medicine.drug
Zdroj:	European journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology. 27(10)
ISSN:	1435-4373
Popis:	Premature infants are vulnerable to severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) resulting in hospitalisation and the potential for longer-term respiratory morbidity. Whilst the severity and consequence of RSV LRTI are generally accepted and recognised in infants born
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37a451a684fe75dbe902443e35bb92d5 https://pubmed.ncbi.nlm.nih.gov/18629558 Zobrazit plný text záznamu Full text from SpringerLink